MAIA Biotechnology, Inc. (MAIA) Current Ratio
- Current ratio · latest quarter: Value 4.51×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.51× | Current assets / current liabilities. $28.24M ÷ $6.26M ≈ 4.51× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 28.24M USD | Assets, Current |
| Current obligations | 6.26M USD | Liabilities, Current |
| Cash and equivalents | 0.00 USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.84M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.24M | $6.26M | $0.00 | (m) | (m) | (m) | $2.84M | (m) | 4.51× |
| 2026-03-31 | $35.32M | $6.32M | $0.00 | (m) | (m) | (m) | $2.98M | (m) | 5.59× |
| 2025-12-31 | $9.70M | $5.84M | $0.00 | (m) | (m) | (m) | $2.04M | (m) | 1.66× |
| 2025-09-30 | $11.75M | $9.99M | $0.00 | (m) | (m) | (m) | $3.18M | (m) | 1.18× |
| 2025-06-30 | $11.04M | $5.04M | $0.00 | (m) | (m) | (m) | $1.72M | (m) | 2.19× |
| 2025-03-31 | $11.86M | $5.06M | $0.00 | (m) | (m) | (m) | $1.84M | (m) | 2.35× |
| 2024-12-31 | $10.15M | $3.83M | $0.00 | (m) | (m) | (m) | $1.51M | (m) | 2.65× |
| 2024-09-30 | $9.24M | $3.61M | $0.00 | (m) | (m) | (m) | $1.15M | (m) | 2.56× |
| 2024-06-30 | $12.02M | $3.51M | $0.00 | (m) | (m) | (m) | $1.26M | (m) | 3.42× |
| 2024-03-31 | $8.70M | $4.91M | $0.00 | (m) | (m) | (m) | $1.87M | (m) | 1.77× |
| 2023-12-31 | $7.56M | $4.94M | $0.00 | (m) | (m) | (m) | $1.64M | (m) | 1.53× |
| 2023-09-30 | $6.63M | $4.15M | $0.00 | (m) | (m) | (m) | $1.23M | (m) | 1.60× |
| 2023-06-30 | $9.78M | $3.27M | $0.00 | (m) | (m) | (m) | $1.55M | (m) | 2.99× |
| 2023-03-31 | $8.33M | $3.77M | $0.00 | (m) | (m) | (m) | $1.13M | (m) | 2.21× |
| 2022-12-31 | $11.81M | $3.27M | $0.00 | (m) | (m) | (m) | $1.17M | (m) | 3.61× |
| 2022-09-30 | $14.78M | $2.46M | $0.00 | (m) | (m) | (m) | $1.02M | (m) | 6.02× |
| 2022-06-30 | $8.61M | $3.10M | $0.00 | (m) | (m) | (m) | $1.04M | (m) | 2.78× |
| 2021-12-31 | $10.67M | $2.15M | $0.00 | (m) | (m) | (m) | $960.40K | (m) | 4.97× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |